ClinicalTrials.gov record
Terminated Phase 1 Interventional

Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus

ClinicalTrials.gov ID: NCT01389895

Public ClinicalTrials.gov record NCT01389895. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 11:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus

Study identification

NCT ID
NCT01389895
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1
Lead sponsor
Amgen
Industry
Enrollment
1 participant

Conditions and interventions

Interventions

  • AMG 557 Drug
  • AMG 557 Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2011
Primary completion
Feb 28, 2013
Completion
Feb 28, 2013
Last update posted
Jan 9, 2014

2011 – 2013

United States locations

U.S. sites
7
U.S. states
4
U.S. cities
5
Facility City State ZIP Site status
Research Site Birmingham Alabama 35233
Research Site Ann Arbor Michigan 48103
Research Site Philadelphia Pennsylvania 19104
Research Site Austin Texas 78705
Research Site Dallas Texas 75231
Not listed Dallas Texas 75231
Research Site Dallas Texas 75235

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01389895, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 9, 2014 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01389895 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →